IP Library › Granted Patent US 7,919,516
Granted Patent B2
US 7,919,516 · App. 12/205,677 · Granted Apr 5, 2011

Deuterium-enriched ondansetron

Assignee: Protia, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,919,516
App. No.
12/205,677
Granted
Apr 5, 2011
Kind
B2
Abstract

The present application describes deuterium-enriched ondansetron, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.

Claims (29)

1. A deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:

wherein the compound is selected from:

1

2

3

4

5

6

or a pharmaceutically acceptable salt thereof, wherein R 1 -R 7 and R 9 -R 19 are independently selected from H and D and R 8 is D and the abundance of deuterium in R 8 is 100%.

2. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

3. A method for treating chemotherapy-induced nausea and vomiting comprising: administering, to a patient in need thereof, a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

4. A compound of claim 1 , wherein the compound is compound 1 or a pharmaceutically acceptable salt thereof.

5. A compound of claim 1 , wherein the compound is compound 2 or a pharmaceutically acceptable salt thereof.

6. A compound of claim 1 , wherein the compound is compound 3 or a pharmaceutically acceptable salt thereof.

7. A compound of claim 1 , wherein the compound is compound 4 or a pharmaceutically acceptable salt thereof.

8. A compound of claim 1 , wherein the compound is compound 5 or a pharmaceutically acceptable salt thereof.

9. A compound of claim 1 , wherein the compound is compound 6 or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition of claim 2 , wherein the compound is compound 1 or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition of claim 2 , wherein the compound is compound 2 or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition of claim 2 , wherein the compound is compound 3 or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition of claim 2 , wherein the compound is compound 4 or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition of claim 2 , wherein the compound is compound 5 or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition of claim 2 , wherein the compound is compound 6 or a pharmaceutically acceptable salt thereof.

16. A method of claim 3 , wherein the compound is compound 1 or a pharmaceutically acceptable salt thereof.

17. A method of claim 3 , wherein the compound is compound 2 or a pharmaceutically acceptable salt thereof.

18. A method of claim 3 , wherein the compound is compound 3 or a pharmaceutically acceptable salt thereof.

19. A method of claim 3 , wherein the compound is compound 4 or a pharmaceutically acceptable salt thereof.

20. A method of claim 3 , wherein the compound is compound 5 or a pharmaceutically acceptable salt thereof.

21. A method of claim 3 , wherein the compound is compound 6 or a pharmaceutically acceptable salt thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2013
From: DEUTERIA PHARMACEUTICALS INC
To: DEUTERX, LLC
Reel/Frame 029731/0423 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2011
From: PROTIA, LLC
To: DEUTERIA PHARMACEUTICALS INCE
Reel/Frame 026609/0689 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2008
From: CZARNIK, ANTHONY W
To: PROTIA, LLC
Reel/Frame 021733/0840 →
Continuity (2)
Provisional Application 60972238 · Sep 13, 2007
Related Publication 20090076107A1 · Mar 19, 2009